DOI: http://dx.doi.org/10.18203/2349-3933.ijam20190990

Rapid-onset supraventricular tachycardia following clozapine initiation and its management with verapamil: a case report

Afnan A. Alwabili

Abstract


Clozapine is the drug of choice for treatment-resistant schizophrenia. However, the use of clozapine is limited by its serious adverse effects, which often underlie its discontinuation. The cardiovascular side effects that raise safety concerns include tachycardia, myocarditis and cardiomyopathy. The development of clozapine-induced tachycardia is usually observed on higher dosage especially at early stages of treatment. Here, author presented the case of a patient with treatment-resistant schizophrenia who developed asymptotic supraventricular tachycardia despite low dose of clozapine at the second day of treatment. Additionally, author explored the possibility of clozapine re-challenge in combination with verapamil treatment.


Keywords


Arrhythmia, Clozapine, Psychosis, Supraventricular tachycardia, Schizophrenia, Verapamil

Full Text:

PDF

References


Meltzer HY. Treatment-resistant schizophrenia-the role of clozapine. Current Med Res Opinion. 1997;14(1):1-20.

Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-96.

Meltzer HY. Dimensions of outcome with clozapine. Brit J Psychiatry. 1992;160(S17):46-53.

Young CR, Longhurst JG, Bowers Jr MB, Mazure CM. The expanding indications for clozapine. Exp Clin Psychopharmacol. 1997;5(3):216.

Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bull. 1991;17(2):247-61.

Rechlin T, Claus D, Weis M. Heart rate variability in schizophrenic patients and changes of autonomic heart rate parameters during treatment with clozapine. Biol Psychiatry. 1994;35(11):888-92.

EMS1. Sinus tach or SVT? 4 clues to tell the difference, 2017. Available at: https://www.ems1.com/ems-products/cpr-resuscitation/articles/191012048-Sinus-tach-or-SVT-4-clues-to-tell-the-difference/.

Grenade LL, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. New Eng J Med. 2001;345(3):224-5.

Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry. 1998;155(8):1113-6.

Stampfer H, Swanepoel P. Severe tachycardia following low-dose clozapine treatment. Aus Psychiatry. 2005;13(1):80-2.

Das P, Kuppuswamy PS, Rai A, Bostwick JM. Verapamil for the treatment of clozapine-induced persistent sinus tachycardia in a patient with schizophrenia: a case report and literature review. Psychosomatics. 2014;55(2):194-5.

Lally J, Brook J, Dixon T, Gaughran F, Shergill S, Melikian N, et al. Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series. Therapeutic Adv Psychopharmacol. 2014;4:117-22.

Settem JV, Trivedi S, Kamath AG, Behere RV, Kanaradi H, Bhat SM. Clozapine-induced supraventricular tachycardia and its treatment with Verapamil. Ind J Psychological Med. 2015;37(3):358.

Kirpekar CV, Faye DA, Gawande S, Tadke R, Bhave SH. Clozapine induced supra ventricular tachycardia. Ind J Psychological Med. 2015;37(2):254.

Saini V, Nebhinani N, Singhai K. Sinus tachycardia with low dose clozapine: a case report. J Ind Assoc Child Adolesc Ment Heal. 2018;14(3):85-90.

Basu S. Dose-dependent clozapine-induced supraventricular tachycardia. Primary Care Companion for CNS Dis. 2016;18(3).

Bartko G, Horvath S, Zador G, Frecska E. Effects of adjunctive verapamil administration in chronic schizophrenic patients. Progress Neuro-psycho-pharmacol Bio Psychiatry. 1991;15(3):343-349.

Kelly JP, Kaufman DW, Shapiro S. Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: the international agranulocytosis and aplastic anemia study. Clin Pharmacol Therapeutics. 1991;49(3):330-41.

Patten SB. Propranolol and depression: evidence from the antihypertensive trials. Can J Psychiatry. 1990;35(3):257-9.

Lally J, Docherty MJ, MacCabe JH. Pharmacological interventions for clozapine‐induced sinus tachycardia. Cochrane Database Sys Rev. 2016; (6).

Davis MC, Fuller MA, Strauss ME, Konicki PE, Jaskiw GE. Discontinuation of clozapine: a 15‐year naturalistic retrospective study of 320 patients. Acta Psychiatrica Scandinavica. 2014;130(1):30-9.